Immutep (NASDAQ:IMMP) Shares Pass Below 50-Day Moving Average – What’s Next?

Shares of Immutep Limited (NASDAQ:IMMP) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.03 and traded as low as $1.93. Immutep shares last traded at $1.94, with a volume of 47,604 shares traded.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird boosted their target price on shares of Immutep from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, November 15th.

Immutep Stock Down 0.5 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The company’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $2.10.

Institutional Investors Weigh In On Immutep

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of Immutep during the second quarter valued at $26,000. XY Capital Ltd grew its holdings in Immutep by 108.3% during the 3rd quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company’s stock worth $239,000 after acquiring an additional 56,344 shares in the last quarter. Finally, Meridian Wealth Management LLC increased its position in Immutep by 4.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after purchasing an additional 17,250 shares during the period. 2.32% of the stock is owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.